Scientists are examining whether intranasal COVID-19 vaccines may be the next step in the development process. Some believe the intranasal vaccines could more effectively protect nasal passages and upper respiratory tracts from virus entry. (STAT)
Harmony Biosciences has secured $330 million in debt capital and equity through a deal with investment firm Blackstone. With the additional funding, Harmony plans to “expand our portfolio of assets in rare, neurological diseases while also reducing our annual interest expense,” CEO John Jacobs said. (Endpoints News)
A new National Institutes of Health study is examining the effect of a third COVID-19 vaccine dose on kidney transplant patients. The agency is hoping to determine whether a booster shot can help immunocompromised patients develop immunity to the virus. (Reuters)
To help address the country’s supply shortages, Moderna will build a vaccine manufacturing plant in Canada. The company plans to discuss similar collaborations with other governments. (CNBC Weekly)
A new study found that adolescents and young people have experienced an increase in depression and suicide risk during the pandemic. The number of young people with depressive symptoms increased from 5 to 6% between the end of 2019 and the end of 2020. (The Washington Post)
